In this issue of Clinical Chemistry, Hung et al. describe the results of a study originally devoted to investigation of the transrenal DNA (Tr-DNA) 1 phenomenon. These authors report on the presence of donorderived, cell-free DNA and cells in the urine of sexmismatched hematopoietic stem cell transplant (HSCT) recipients (1 ).
In this issue of Clinical Chemistry, Hung et al. describe the results of a study originally devoted to investigation of the transrenal DNA (Tr-DNA) 1 phenomenon. These authors report on the presence of donorderived, cell-free DNA and cells in the urine of sexmismatched hematopoietic stem cell transplant (HSCT) recipients (1 ) .
The term Tr-DNA defines DNA molecules that appear in the urine from sources located outside of the urinary system. The investigators who found such molecules in urine for the first time suggested that DNA fragments from cells dying throughout the body appear in the bloodstream as so-called cell-free circulating DNA (cfcDNA) and then cross the kidney barrier into the urine (2 ) . Otherwise, it is difficult to explain how fetal DNA appears in the urine of pregnant women or how tumor-specific DNA markers appear in the urine of patients with tumors located outside of the urinary system. This original observation was reproduced in many laboratories (2) (3) (4) (5) (6) (7) . At the same time, several groups could not detect fetal DNA in the urine of pregnant women (8, 9 ) , raising doubts about the concept of Tr-DNA. The latter results can be explained by the fact that Tr-DNA fragments are shorter than cfcDNA, and shorter amplicons should be used for their detection (4, 7, 10 ) , especially in prenatal models in which concentrations of fetal DNA in maternal urine are low. It is also important to remember that urinary DNA from other sources complicates analysis of Tr-DNA. Other sources of urinary DNA include epithelial cells shed from the organs of the urinary system, often lymphocytes and other white blood cells, and cell-free DNA released into the urine after chromatin degradation in cells dying in the kidney and bladder. Bacterial infection is another potential source of urinary DNA; hence urine is widely used for diagnosing sexually transmitted diseases (11, 12 ) .
As a model for investigation of the Tr-DNA phenomenon, Hung and colleagues studied HSCT recipients, whose plasma contains a significant amount of donor-specific cfcDNA. The primary goal of the study was to find out if there is a correlation between concentrations and sizes of cfcDNA in the plasma and Tr-DNA in the urine. To simplify detection of donor DNA in plasma and urine, the authors selected sexmismatched HSCT recipients. Twenty-one of 22 patients had more than 99% of donor lymphohematopoietic cells in the peripheral blood. To differentiate male and female DNA, a zinc finger-protein gene assay was designed based on the nucleotide difference between the zinc finger-protein genes located on chromosomes X and Y. In addition, Y chromosome-specific SRY sequences were used for male donor/female recipient patients. The contribution of donor-derived cfcDNA in plasma was in the range of 72.8%-79.3%, supporting the earlier conclusion about the predominantly hematopoietic origin of cfcDNA in plasma (13 ) . These data indicate that only about 25% of cfcDNA is delivered to the bloodstream by other tissues. However, one should keep in mind that in spite of all precautions undertaken by the authors, it is very difficult to design experiments that will unambiguously exclude damage of a small number of white blood cells with subsequent release of DNA into plasma during blood collection and centrifugation. Assuming that blood contains about 5 million white blood cells per mL, one can calculate that death of 1/1000 cells during blood collection and plasma preparation can lead to release of 5000 DNA genome equivalents, or Ͼ30 ng DNA/mL. In particular, this source of DNA can explain the very broad range of cfcDNA concentrations in plasma reported by different authors.
After analysis of cfcDNA in plasma, Hung et al. investigated urinary DNA. The mean fractional concentration of male DNA was 92.3% in the urine of male sex-mismatched HSCT recipients, a result that is not surprising because most of this DNA came from cells shed from the kidney and bladder or dying in situ. More interestingly, urine supernatants from female sex-mismatched HSCT recipients also contained significant amounts (26%-88.1%) of male, and thus donor-derived, DNA. When the fractional concentrations of cell-free donor-derived DNA in urine supernatants and plasma were compared, no correlation was found. This result was expected because the percentage of donor DNA in the urine supernatant depends on several widely variable factors: (a) the amount of the cell-free recipient DNA from urinary cells dying in situ or in the urine; (b) the amount of white blood cells, which are mainly donor-derived, present in the urine; and (c) the amount of plasma cellfree DNA, which is a source of Tr-DNA.
In the next set of experiments, Hung et al. used primers for SRY amplicons in the range of 63-377 bp to compare the lengths of donor-derived cell-free DNA in urine and plasma of 5 female sex-mismatched HSCT recipients. Large DNA fragments were found in cellfree urinary DNA but not in cfcDNA in plasma. Again, because donor-derived white blood cells are present in the urine, where at least some of them are dying, one should expect the presence of large fragments of donor DNA in urine supernatants.
Thus, the data obtained do not support but also do not contradict the Tr-DNA concept. Systems that exclude the appearance of cells from tissues located outside of urinary tract and bearing specific DNA markers in the urine would be more informative from this viewpoint. One such system, in patients with nasopharyngeal carcinoma, was investigated in the same laboratory. The authors found not only sequences of tumor-specific Epstein-Barr virus in the urine of these patients but also a correlation between the concentrations of transrenal Epstein-Barr virus DNA and Epstein-Barr virus cfcDNA in plasma (7 ).
Because Hung et al.
(1 ) did not find any correlation between concentrations and lengths of donorderived DNA in plasma and urine supernatants, they performed more detailed analyses of cells from the urine sediments. Using FISH with probes for X and Y chromosomes, Hung et al. easily detected donor cells in all urine samples, a finding that explained the results discussed above. In addition to this, however, as a reward for the carefully performed study, the authors found something else: a small proportion of donor cells in some samples were morphologically similar to urinary epithelial cells. Therefore, the investigators analyzed the urinary sediments more carefully, combining FISH with immunofluorescent detection of cytokeratin (CK) as an epithelial marker. All 10 sexmismatched HSCT recipients had recipient-derived CK-positive epithelial cells and CK-negative donorderived white blood cells. Surprisingly, in urine sediments of 3 patients a small amount (0.4%Ϫ1.3%) of donor-derived CK-positive epithelial cells was found. At the time of urine collection, these patients were 2.3, 3.7, and 14.2 years posttransplantation. More studies are necessary to explain this phenomenon, but currently the authors' suggestion about differentiation of bone marrow-derived stem cells into epithelial tubular cells looks reasonable. The plasticity of hematopoietic stem cells (14, 15 ) as well as their involvement in renal repair (16, 17 ) has already been well documented and intensively investigated. Because of the absence of available approaches for investigation of the phenomenon in clinical patients, however, all these data were obtained in animal models. If confirmed in larger clinical studies, the observations of Hung et al. may have important biological and medical consequences, providing a model for better understanding of in vivo stem cell differentiation and potential therapeutic applications of this phenomenon. 
